专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08067000B2 Cancer treatment with endothelin receptor antagonists 有权
标题翻译：内皮素受体拮抗剂治疗癌症
公开(公告)号：US08067000B2
公开(公告)日：2011-11-29
申请号：US12470589
申请日：2009-05-22
申请人： Robert J. Schneider , Sumayah Jamal
发明人： Robert J. Schneider , Sumayah Jamal
IPC分类号： A61K38/00 , A61K39/395 , A61P35/00
CPC分类号： A61K39/39558 , A61K31/7088 , A61K38/00 , C07K14/57536 , G01N33/5011 , G01N33/57407 , G01N33/74 , G01N2333/5754 , G01N2500/04
摘要： The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.
摘要翻译：本发明涉及设计用于治疗和预防癌症的治疗方案和药物组合物。更具体地，本发明涉及使用内皮素B受体（ETB）的拮抗剂或内皮素-1的无活性模拟形式治疗癌症的新方法。本发明的药物组合物能够选择性地抑制与癌症发展相关的早期事件。本发明进一步涉及筛选测定以抑制ETB活化的化合物。

2. 发明授权

US07566452B1 Cancer treatment with endothelin receptor antagonists 失效
标题翻译：用内皮素受体拮抗剂治疗癌症
公开(公告)号：US07566452B1
公开(公告)日：2009-07-28
申请号：US09305084
申请日：1999-05-04
申请人： Robert J. Schneider , Sumayah Jamal
发明人： Robert J. Schneider , Sumayah Jamal
IPC分类号： A61K39/395 , A61K38/00 , G01N33/53
CPC分类号： A61K39/39558 , A61K31/7088 , A61K38/00 , C07K14/57536 , G01N33/5011 , G01N33/57407 , G01N33/74 , G01N2333/5754 , G01N2500/04
摘要： The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.
摘要翻译：本发明涉及设计用于治疗和预防癌症的治疗方案和药物组合物。更具体地，本发明涉及使用内皮素B受体（ETB）的拮抗剂或内皮素-1的无活性模拟形式治疗癌症的新方法。本发明的药物组合物能够选择性地抑制与癌症发展相关的早期事件。本发明进一步涉及筛选测定以抑制ETB活化的化合物。

3. 发明授权

US5202070A Method for making composite products having an integral knit matrix 失效
标题翻译：制造具有整体针织矩阵的复合制品的方法
公开(公告)号：US5202070A
公开(公告)日：1993-04-13
申请号：US649634
申请日：1991-02-01
申请人： Robert J. Schneider
发明人： Robert J. Schneider
IPC分类号： B29C70/22 , B29C70/30 , D04B1/00 , D04B1/22
CPC分类号： D04B1/16 , B29C70/222 , B29C70/30 , D04B1/22 , D10B2403/0113 , D10B2403/023 , D10B2403/0333 , D10B2505/02
摘要： A method of forming a rigid composite varishaped product by knitting an integral fabric piece in the desired shape and impregnating the knitted piece with a selected settable impregnate which is then set; the products made from the method including the intermediate knitted products and the process for making the intermediate product and the knitting program for directing the needles of the knitting machine on which the intermediate product is made.
摘要翻译：通过将整体织物编织成所需形状并用选定的可固化浸渍浸渍针织物，形成刚性复合变形产品的方法; 由包括中间针织产品和中间产品制造方法的方法制成的产品以及用于引导制造中间产品的针织机的针的编织程序。

4. 发明申请

US20180163178A1 AUF1 ENCODING COMPOSITIONS FOR MUSCLE CELL UPTAKE, SATELLITE CELL POPULATIONS, AND SATELLITE CELL MEDIATED MUSCLE GENERATION 审中-公开
公开(公告)号：US20180163178A1
公开(公告)日：2018-06-14
申请号：US15577851
申请日：2016-05-27
申请人： Robert J. SCHNEIDER , Devon M. CHENETTE
发明人： Robert J. SCHNEIDER , Devon M. CHENETTE
IPC分类号： C12N5/077 , C07K14/435 , A01K67/027 , C12Q1/6883 , A61P21/00 , C12N15/86
CPC分类号： C12N5/0659 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0306 , A61P21/00 , C07K14/435 , C07K14/4703 , C12N15/86 , C12N2015/8536 , C12Q1/68 , C12Q1/6883
摘要： The present invention relates to compositions (e.g., AUF1 encoding compositions) for muscle cell uptake, satellite cell populations and compositions containing muscle satellite cell populations, pharmaceutical compositions, methods of producing muscle satellite cell compositions, and methods of causing muscle satellite cell mediated muscle generation.

5. 发明申请

US20120148602A1 Cancer Treatment With Endothelin Receptor Antagonists 有权
标题翻译：内皮素受体拮抗剂治疗癌症
公开(公告)号：US20120148602A1
公开(公告)日：2012-06-14
申请号：US13267360
申请日：2011-10-06
申请人： Robert J. Schneider , Sumayah Jamal
发明人： Robert J. Schneider , Sumayah Jamal
IPC分类号： A61K39/395 , A61P35/00 , G01N33/567 , A61K31/7088
CPC分类号： A61K39/39558 , A61K31/7088 , A61K38/00 , C07K14/57536 , G01N33/5011 , G01N33/57407 , G01N33/74 , G01N2333/5754 , G01N2500/04
摘要： The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.
摘要翻译：本发明涉及设计用于治疗和预防癌症的治疗方案和药物组合物。更具体地，本发明涉及使用内皮素B受体（ETB）的拮抗剂或内皮素-1的无活性模拟形式治疗癌症的新方法。本发明的药物组合物能够选择性地抑制与癌症发展相关的早期事件。本发明进一步涉及筛选测定以抑制ETB活化的化合物。

6. 发明申请

US20110246153A1 METHOD FOR PELLET CLADDING INTERACTION (PCI) EVALUATION AND MITIGATION DURING BUNDLE AND CORE DESIGN PROCESS AND OPERATION 审中-公开
标题翻译：芯片封装交互（PCI）评估和缓解方法在芯片设计过程和操作过程中的应用
公开(公告)号：US20110246153A1
公开(公告)日：2011-10-06
申请号：US12753968
申请日：2010-04-05
申请人： Benjamin James Schultz , Michael William Thomas , Shawn Marie Lamb , Harold Hartney Yeager , Robert J. Schneider , Charles Carter McNeely , Richard Augi
发明人： Benjamin James Schultz , Michael William Thomas , Shawn Marie Lamb , Harold Hartney Yeager , Robert J. Schneider , Charles Carter McNeely , Richard Augi
IPC分类号： G06G7/54 , G06G7/48
CPC分类号： G21D3/00 , G21C3/047 , G21C7/00 , G21C17/00 , G21C19/205 , G21D3/002 , Y02E30/39
摘要： Example embodiments are directed to a method of fuel bundle design, core design, or combined fuel and core design, to ensure Pellet Cladding Interaction (PCI) related fuel failures are mitigated. More specifically, example embodiments provide fuel and/or core designs that may be determined prior to operation of a nuclear power plant, or prior to production of fresh fuel bundles. The PCI optimized fuel/core designs may include some or all of seven PCI Evaluation Methods which may be incorporated into existing nuclear reactor simulation programs. PCI optimized fuel and/or core design enhances fuel reliability, allows faster beginning-of-cycle (BOC) startups and faster middle-of-cycle (MOC) sequence exchanges to maximize plant performance, and minimizes ramping restrictions, thereby maximizing nuclear power plant performance.
摘要翻译：示例性实施例涉及燃料束设计，核心设计或组合的燃料和核心设计的方法，以确保减轻相关的颗粒包层相互作用（PCI）的燃料故障。更具体地，示例性实施例提供可以在核电厂运行之前或在生产新鲜燃料束之前确定的燃料和/或核心设计。 PCI优化的燃料/核心设计可以包括可以并入现有核反应堆模拟程序的七种PCI评估方法中的一些或全部。 PCI优化的燃料和/或核心设计提高了燃料可靠性，允许更快的起始周期（BOC）启动和更快的中期循环（MOC）序列交换，以最大化工厂性能，并最大限度地减少斜坡限制，从而最大化核电站性能。

7. 发明申请

US20100003240A1 CANCER TREATMENT WITH ENDOTHELIN RECEPTOR ANTAGONISTS 有权
标题翻译：内皮素受体拮抗剂治疗癌症
公开(公告)号：US20100003240A1
公开(公告)日：2010-01-07
申请号：US12470589
申请日：2009-05-22
申请人： Robert J. Schneider , Sumayah Jamal
发明人： Robert J. Schneider , Sumayah Jamal
IPC分类号： A61K39/395 , A61K38/12 , A61K31/445 , A61P35/04
CPC分类号： A61K39/39558 , A61K31/7088 , A61K38/00 , C07K14/57536 , G01N33/5011 , G01N33/57407 , G01N33/74 , G01N2333/5754 , G01N2500/04
摘要： The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.
摘要翻译：本发明涉及设计用于治疗和预防癌症的治疗方案和药物组合物。更具体地，本发明涉及使用内皮素B受体（ETB）的拮抗剂或内皮素-1的无活性模拟形式治疗癌症的新方法。本发明的药物组合物能够选择性地抑制与癌症发展相关的早期事件。本发明进一步涉及筛选测定以抑制ETB活化的化合物。

8. 发明授权

US5822023A Projected display system for a vehicle 失效
标题翻译：预计车辆显示系统
公开(公告)号：US5822023A
公开(公告)日：1998-10-13
申请号：US25189
申请日：1993-03-02
申请人： Michael J. Suman , Thomas L. Welling , Robert J. Schneider
发明人： Michael J. Suman , Thomas L. Welling , Robert J. Schneider
IPC分类号： B60R11/00 , B60R11/02 , H04N5/64 , H04N5/74 , H04N7/18
CPC分类号： B60R7/04 , B60R11/0229 , B60R11/0235 , H04N9/3141 , B60R11/0264 , B60R2011/0028 , B60R2011/0082 , B60R2011/0276
摘要： A projection system for projecting television images in a vehicle including a console for mounting to the roof of a vehicle with a housing in which a video projector for television signals is fixedly mounted. The console further includes a cover which is pivotally mounted to the housing at its forward end for movement between a closed position, substantially enclosing the projector, and an open position. A projection screen is movably mounted to the housing to move the screen between a substantially horizontal stored position within the cover and housing, and a substantially vertical use position when the cover is opened. The console further includes, in a preferred embodiment, light blocking panels coupled between the cover and housing for enclosing the sides of the space between the projector and screen for providing a dark environment between the projector and the surface of the screen facing the projector.
摘要翻译：一种用于在车辆中投影电视图像的投影系统，包括用于安装到具有用于电视信号的视频投影仪的外壳的车辆的车顶的控制台。控制台还包括一个盖子，该盖子在其前端枢转地安装到壳体上，用于在基本上包围投影机的关闭位置和打开位置之间移动。投影屏幕可移动地安装到壳体，以在屏幕和外壳之间的基本上水平的存储位置之间移动屏幕，并且在打开盖时基本垂直使用位置。在优选实施例中，控制台还包括耦合在盖和壳体之间的遮光板，用于封闭投影仪和屏幕之间的空间的侧面，以在投影仪和面向投影仪的屏幕的表面之间提供暗环境。

9. 发明授权

US4882269A Amplified hybridization assay 失效
标题翻译：扩增杂交测定
公开(公告)号：US4882269A
公开(公告)日：1989-11-21
申请号：US940712
申请日：1986-12-11
申请人： Robert J. Schneider , Thomas E. Shenk
发明人： Robert J. Schneider , Thomas E. Shenk
IPC分类号： G01N33/50 , C07H21/00 , C12N15/00 , C12N15/09 , C12Q1/00 , C12Q1/34 , C12Q1/44 , C12Q1/68
CPC分类号： C07H21/00 , C12Q1/6813 , C12Q1/682 , Y10S435/803 , Y10S435/81 , Y10S436/80 , Y10S436/805 , Y10S436/808
摘要： An amplified hybridization assay is described in which a family of signal-generating secondary probes bind to a primary probe that hybridizes to the target sequence of interest. Thus, an enormously amplified signal is generated by the hybridization event. The assay can be used for a variety of laboratory and clinical purposes and is automatable.
摘要翻译：描述了扩增杂交测定法，其中产生信号的第二探针家族与与目标靶序列杂交的主要探针结合。因此，通过杂交事件产生极大的放大信号。该测定可用于各种实验室和临床目的，并且是可自动化的。

10. 发明授权

US5424188A Amplified hybridization assay 失效
标题翻译：扩增杂交测定
公开(公告)号：US5424188A
公开(公告)日：1995-06-13
申请号：US963923
申请日：1992-10-20
申请人： Robert J. Schneider , Thomas E. Shenk
发明人： Robert J. Schneider , Thomas E. Shenk
IPC分类号： G01N33/50 , C07H21/00 , C12N15/00 , C12N15/09 , C12Q1/00 , C12Q1/34 , C12Q1/44 , C12Q1/68 , C07H21/04
CPC分类号： C07H21/00 , C12Q1/6813 , C12Q1/682 , Y10S435/803 , Y10S435/81 , Y10S436/80 , Y10S436/805 , Y10S436/808
摘要： A kit for an amplified hybridization assay is described in which a family of signal-generating secondary probes bind to a primary probe that hybridizes to the target sequence of interest. Thus, an enormously amplified signal is generated by the hybridization event. The assay can be used for a variety of laboratory and clinical purposes and is automatable. A hybridization assay kit is also described. The kit is used for the detection of a target nucleotide sequence. One embodiment of the kit includes a plurality of secondary probes, each secondary probe capable of binding to a distinct binding site of the primary probe.
摘要翻译：描述了用于扩增杂交测定的试剂盒，其中产生信号的二级探针家族与与目标靶序列杂交的主要探针结合。因此，通过杂交事件产生极大的放大信号。该测定可用于各种实验室和临床目的，并且是可自动化的。还描述了杂交测定试剂盒。该试剂盒用于检测靶核苷酸序列。试剂盒的一个实施方案包括多个第二探针，每个次级探针能够结合主探针的不同结合位点。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式